KALEIDO
VL32, Inc.
Trademark Registered: 2019-12-17
Trademark Application Details
NOTICE OF ALLOWANCE - ISSUED
| Research |
OneLook
Acronym Finder
|
| Serial Number | 86783357 |
| Registration Number | 5938245 |
| Mark Drawing Code | 4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form |
| Attorney Name | Christina Licursi |
| Attorney Docket Number | V0279.20001U |
| Law Office Assigned | L10 |
| Employee Name | WEIGLE, KATHERINE CONN |
Timeline
| 2015-10-09 | Application Filed |
| 2018-08-28 | Published for Opposition |
| 2018-10-23 | Location: INTENT TO USE SECTION |
| 2018-10-23 | Status: Live/Pending |
| 2019-01-03 | Transaction Date |
| 2019-12-17 | Trademark Registered |
Trademark Applicants & Owners
| Owner: |  VL32, Inc. |
| Address | 1 Memorial Drive, 7th Floor Cambridge DE 02142 |
| Legal Entity Type | Corporation |
| Legal Entity State | DE |
Documents
Click the blue "Refresh" button to load certificates, specimines, application, and other documents.
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis |
| GS0051 | preparations and substances for pharmaceutical and medical purposes, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis; therapeutic pharmaceuticals for medical use, namely, for the treatment of dysbioses, inflammatory disorders and conditions, infectious diseases, metabolic diseases, nutritional disorders, malnutrition, immune-mediated diseases, including autoimmune diseases, allergies, and immune tolerance, malignancies and cancers, neurological diseases, psychiatric conditions, gastrointestinal diseases and disorders, gastrointestinal injury conditions, digestive abnormalities, dermatological conditions, cardiovascular diseases, nephrologic diseases and conditions, including organ failure, ophthalmic disorders, vaginal and penile conditions, pediatric disorders and conditions, including growth and developmental conditions, and geriatric disorders and conditions, all of the foregoing related to the microbiome and all of the foregoing excluding treatments for cystic fibrosis |
Trademark Filing History
| Description | Date | Event Coding |
|---|---|---|
| NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2015-10-15 | 1 NWOS I:Incoming Correspondence |
| ASSIGNED TO EXAMINER | 2016-02-01 | 2 DOCK D:Assigned to Examiner |
| NON-FINAL ACTION WRITTEN | 2016-02-08 | 3 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2016-02-08 | 4 GNRT F:First Action |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2016-02-08 | 5 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2016-08-08 | 6 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2016-08-08 | 7 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2016-08-09 | 8 TEME I:Incoming Correspondence |
| NON-FINAL ACTION WRITTEN | 2016-08-24 | 9 CNRT R:Renewal |
| NON-FINAL ACTION E-MAILED | 2016-08-24 | 10 GNRT O:Outgoing Correspondence |
| NOTIFICATION OF NON-FINAL ACTION E-MAILED | 2016-08-24 | 11 GNRN O:Outgoing Correspondence |
| TEAS RESPONSE TO OFFICE ACTION RECEIVED | 2017-02-16 | 12 TROA I:Incoming Correspondence |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-02-16 | 13 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2017-02-16 | 14 TEME I:Incoming Correspondence |
| AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | 2017-02-22 | 15 ASGN I:Incoming Correspondence |
| FINAL REFUSAL WRITTEN | 2017-03-08 | 16 CNFR R:Renewal |
| FINAL REFUSAL E-MAILED | 2017-03-08 | 17 GNFR O:Outgoing Correspondence |
| NOTIFICATION OF FINAL REFUSAL EMAILED | 2017-03-08 | 18 GNFN O:Outgoing Correspondence |
| EXPARTE APPEAL RECEIVED AT TTAB | 2017-09-06 | 19 EXAF T:TTAB Proceeding |
| JURISDICTION RESTORED TO EXAMINING ATTORNEY | 2017-09-06 | 20 JURT T:TTAB Proceeding |
| EX PARTE APPEAL-INSTITUTED | 2017-09-06 | 21 EXPI T:TTAB Proceeding |
| TEAS REQUEST FOR RECONSIDERATION RECEIVED | 2017-09-06 | 22 ERFR I:Incoming Correspondence |
| ASSIGNED TO LIE | 2017-09-13 | 23 ALIE A:Allowance for Publication |
| CORRESPONDENCE RECEIVED IN LAW OFFICE | 2017-09-20 | 24 CRFA I:Incoming Correspondence |
| TEAS/EMAIL CORRESPONDENCE ENTERED | 2017-09-20 | 25 TEME I:Incoming Correspondence |
| ACTION CONTINUING FINAL - COMPLETED | 2017-09-26 | 26 CNCF S: |
| ACTION DENYING REQ FOR RECON E-MAILED | 2017-09-26 | 27 GECD O:Outgoing Correspondence |
| NOTIFICATION OF ACTION DENYING REQ FOR RECON E-MAILED | 2017-09-26 | 28 GEA1 O:Outgoing Correspondence |
| JURISDICTION RESTORED TO EXAMINING ATTORNEY | 2018-07-24 | 29 JURT T:TTAB Proceeding |
| ASSIGNED TO EXAMINER | 2018-07-24 | 30 DOCK D:Assigned to Examiner |
| APPROVED FOR PUB - PRINCIPAL REGISTER | 2018-07-25 | 31 CNSA P: |
| EXPARTE APPEAL TERMINATED | 2018-07-25 | 32 EXPT T:TTAB Proceeding |
| NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2018-08-08 | 33 NONP E:E-Mail |
| PUBLISHED FOR OPPOSITION | 2018-08-28 | 34 PUBO A:Allowance for Publication |
| OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2018-08-28 | 35 NPUB E:E-Mail |
| NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2018-10-23 | 36 NOAM E:E-Mail |
| TEAS CHANGE OF OWNER ADDRESS RECEIVED | 2019-01-02 | 37 COAR I:Incoming Correspondence |
| APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 2019-01-02 | 38 CHAN I:Incoming Correspondence |
| TEAS EXTENSION RECEIVED | 2019-04-23 | 39 EEXT I:Incoming Correspondence |
| EXTENSION 1 FILED | 2019-04-23 | 40 EXT1 S: |
| EXTENSION 1 GRANTED | 2019-04-23 | 41 EX1G S: |
| NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2019-04-25 | 42 EXRA E:E-Mail |
| TEAS STATEMENT OF USE RECEIVED | 2019-10-18 | 43 EISU I:Incoming Correspondence |
| CASE ASSIGNED TO INTENT TO USE PARALEGAL | 2019-11-02 | 44 AITU A:Allowance for Publication |
| USE AMENDMENT FILED | 2019-10-18 | 45 IUAF S: |
| STATEMENT OF USE PROCESSING COMPLETE | 2019-11-04 | 46 SUPC I:Incoming Correspondence |
| ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | 2019-11-12 | 47 CNPR P: |
| NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | 2019-11-13 | 48 SUNA E:E-Mail |
| REGISTERED-PRINCIPAL REGISTER | 2019-12-17 | 49 R.PR A:Allowance for Publication |
Similar Marks
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 